SCHEMBL5863607

SCHEMBL5863607

CCNC(=O)C1(CCCN2CCN(c3ccc4c(c3)C(=O)N(Cc3cccc(C)c3)CC4)CC2)c2ccccc2-c2ccccc21

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.45
DRD3 P35462 10/20 0.43
DRD2 P14416 4/20 0.43
DRD1 P21728 3/20 0.43
SMN1; SMN2 Q16637 4/20 0.39
PKM P14618 2/20 0.39
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 2/20 0.39
DRD4 P21917 1/20 0.38
HTT P42858 1/20 0.38
HTR1A P08908 3/20 0.38
HTR2A P28223 3/20 0.38
HTR2C P28335 3/20 0.38
KCNH2 Q12809 1/20 0.38
TP53 P04637 1/20 0.37
KMT2A Q03164 1/20 0.37
TMEM97 Q5BJF2 1/20 0.37
SIGMAR1 Q99720 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5863897 0.98 DRD3 (0.44) LMNADRD3DRD2DRD1SMN1; SMN2
SCHEMBL5863554 0.94 LMNA (0.43) LMNADRD3DRD2DRD1SMN1; SMN2
SCHEMBL5863677 0.93 LMNA (0.45) LMNADRD3DRD2DRD1ALDH1A1
SCHEMBL5864148 0.93 DRD3 (0.44) DRD3DRD2DRD1DRD4HTR1A
SCHEMBL5863395 0.93 LMNA (0.43) LMNADRD3DRD2DRD1SMN1; SMN2
SCHEMBL5864096 0.92 HTR7 (0.43) DRD3DRD2DRD1DRD4HTR1A
SCHEMBL5863801 0.92 DRD3 (0.43) LMNADRD3DRD2DRD1SMN1; SMN2
SCHEMBL5863973 0.92 LMNA (0.44) LMNADRD3DRD2DRD1KCNH2
SCHEMBL5864151 0.92 LMNA (0.43) LMNADRD3DRD2DRD1SMN1; SMN2
SCHEMBL5863733 0.91 LMNA (0.45) LMNADRD3DRD2DRD1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030120-B2 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-18 US disclosed
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same OHKURA NAOTO (JP) 2004-11-11 US disclosed
US-6777414-B1 INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA MEIJI SEIKA KAISHA, LTD. (JP) 2004-08-17 US disclosed
EP-1180514-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2002-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same APOB, NCEH1, LIPC LMNA 508/4885DRD3 862/4885DRD2 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.